Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biotricity, Inc. - Common Stock (NQ: BTCY )

0.4631 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biotricity, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024
Via ACCESSWIRE
Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
Via ACCESSWIRE
Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
Via ACCESSWIRE
Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats
Via ACCESSWIRE
Biotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024
Via ACCESSWIRE
Biotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14th
Via ACCESSWIRE
CORRECTION BY SOURCE: Biotricity Announces Patent Filing for Cutting-Edge Biotres Device
Via ACCESSWIRE
Biotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge Innovations
Via ACCESSWIRE
Biotricity Releases Another Groundbreaking Product: Biotres Pro
Via ACCESSWIRE
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device
Via ACCESSWIRE
Biotricity Announces Patient Filing for Cutting-Edge Biotres Device
Via ACCESSWIRE
Biotricity Achieves $14 Million Revenue Run Rate in August 2023
Via ACCESSWIRE
Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates
Via ACCESSWIRE
Biotricity Shows Continued Growth and Strength in its Fundamentals on its Path to Profitability
Via ACCESSWIRE
Biotricity Reports Strong Start to Fiscal Year 2024
Via ACCESSWIRE
Biotricity to Host Fiscal Year 2023 Financial Results and Business Update Call on June 30th
Via ACCESSWIRE
Biotricity to Host First Quarter Fiscal Year 2024 Financial Results and Business Update Call on August 15th
Via ACCESSWIRE
Biotricity Is Paving The Way For Cardiac Health In The Age Of AI Technology
Via ACCESSWIRE
Biotricity Expands Its Proprietary AI Model and Deepens Relationship with Amazon AWS and Google's Tensor Flow for Remote Cardiac Care Applications
Via ACCESSWIRE
Biotricity Regains Nasdaq Listing Compliance
Via ACCESSWIRE
Biotricity Announces Reverse Stock Split
Via ACCESSWIRE
Biotricity CEO Speaks to the Future of AI and its Contributions to Healthcare
Via ACCESSWIRE
Biotricity Reaches $13M Revenue Run Rate in April 2023 on Accelerating Growth
Via ACCESSWIRE
Biotricity's Founder & CEO Waqaas Al-Siddiq to Present at World Heart Summit May 19-21 in Geneva, Switzerland
Via ACCESSWIRE
Biotricity Reports Business Update, Financial Results for Q4 and Full Year FY23; Company Posts Robust Revenue Growth, Overall Higher Margins, with Lower SG&A Driving Clear Path to Positive Cash Flow
Via ACCESSWIRE
New Report Reveals Medtech Company Biotricity Decreased Patient Spending By Millions While Delivering Life-Saving Products
Via ACCESSWIRE
Biotricity Reaches $12M Revenue Run Rate in March with Promising Future Growth Ahead
Via ACCESSWIRE
Leading Medical Biometric Firm Biotricity Releases First Corporate Impact Report
Via ACCESSWIRE
Medical Biometric Firm Biotricity Reshaping Market Through Pioneering Innovation
Via ACCESSWIRE
Biotricity Reports Financial Results for Fiscal 2023 Third Quarter
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.